arrow_back Back Filing freshness 10-Q Q3 FY2026 SEC EDGAR

RxSight, Inc.

RXST
$4.52 ▼ -0.46 (-9.24%) at close
Industrials ·Ophthalmic Goods ·USOphthalmic Goods
26 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
18
Health
Poor
Bearish
auto_awesome

Analytical Summary

RxSight, Inc. faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $188.5M
Dividend Yield —
Revenue Growth -19.0% ↘
Op. Margin -75.3% ↘
ROIC -7.3% ↘
FCF / Share $1.06 ↗
Trailing P/E —
Price / Book 0.7x
FCF Yield 23.4%
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

26-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$24.59M
↓ -19.0% —
Net Income Profit after all expenses
$-15.88M
↓ -93.9% —
Operating Margin Operating profit as % of sales
-75.3%
↓ -84.6% 7th
FCF / Share Free cash flow per share
$1.06
↑ +481.2% —
Long-Term Debt Long-term obligations
$0.00
↓ -100.0% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↑
8
Returns ↑
31
Financial Health ↓
2
Cash Quality ↓
40

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 6 years · 26 quarters